Life Sciences

  • August 10, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week tackled disputes involving merger settlements, contract claims, controlling stockholders, music rights, prejudgment interest, absentee voting and stockholder standing.

  • August 10, 2026

    Jazz Pharma Buying Actio In Up To $1.32B Epilepsy Push

    Dublin-based Jazz Pharmaceuticals PLC said Monday it will pay up to $1.32 billion for privately held Actio Biosciences, with Hogan Lovells Cadwalader advising Jazz and Cooley LLP guiding Actio. 

  • August 10, 2026

    EU Sets Antidumping Duties On Plastic Compound Imports

    A chemical compound used in plastic production has been found to have been sold at less than fair value in the European Union, and imports from South Korea and Mexico will face antidumping duties, the European Commission announced Monday.

  • August 07, 2026

    3rd Circ. Says Pharma Co. Suit Against Merck Belongs In India

    The Third Circuit has ruled that a dispute between Merck and a defunct Indian pharmaceutical company over a terminated relationship belongs in India.

  • August 07, 2026

    VA To Test Psilocybin For Veterans With Severe Depression

    Former military service members in five U.S. cities will have an opportunity to treat their depression with psilocybin through a clinical trial being run by the U.S. Department of Veterans Affairs, according to an agency announcement.

  • August 07, 2026

    Glenmark's $29.6M Generics Price-Fixing Deal Gets 1st OK

    A Connecticut federal court on Thursday gave a preliminary OK to a settlement between a coalition of 48 states and territories and drugmaker Glenmark Pharmaceuticals Ltd. that would pay out more than $29.6 million in restitution to eligible consumers and the coalition.

  • August 07, 2026

    J&J Fax Sent To Pharmacy An Unwanted Ad, 3rd Circ. Says

    In a precedential opinion Friday, the Third Circuit ruled a two-page fax Johnson & Johnson sent to a Florida pharmacy about its drug Xarelto was an unsolicited advertisement, reversing a lower court's finding and reviving a class claim filed by the pharmacy alleging the drugmaker violated the Telephone Consumer Protection Act.

  • August 07, 2026

    New Squires Order Institutes 4 Patent Reviews, Denies 6

    U.S. Patent and Trademark Office Director John Squires has instituted review of four patents and denied six other petitions in his latest round of decisions.

  • August 07, 2026

    KKR Buying Medicover's India Business In $1.4B Deal

    Global investment firm KKR has agreed to acquire Medicover Hospitals India, Swedish healthcare provider Medicover AB's Indian hospital operations business, in a transaction that values the platform at about €1.2 billion ($1.4 billion).

  • August 07, 2026

    Nat'l Science Org. To Review Judiciary's Nixed Climate Chapter

    The National Academy of Sciences will review the process used to develop a controversial chapter on climate science that has been removed from the federal judiciary's guide to scientific evidence, according to a Friday announcement.

  • August 07, 2026

    Eli Lilly Launches Attacks On Tirzepatide Generics

    Eli Lilly and Co. fired off a round of lawsuits in Delaware federal court seeking to block generic versions of its tirzepatide weight loss and diabetes medications, targeting Sandoz, MSN Laboratories and others.

  • August 07, 2026

    Cooley Leads 2 Biotech Firms Pricing IPOs Totaling $496M

    Two biotechnology firms began trading publicly Friday after raising a combined $496 million in their initial public offerings, with Cooley LLP advising both companies and Latham & Watkins LLP advising both underwriters.

  • August 07, 2026

    Taxation With Representation: Slaughter And May, Covington

    In this week's Taxation With Representation, U.K. real estate investment trust Segro's board agrees to a share offer from U.S. rival Prologis with a partial cash alternative, Curium acquires fellow radiopharmaceutical company Lantheus Holdings Inc., and investment firm KKR buys medical device company Integer Holdings Corp.

  • August 06, 2026

    Mead Preemption Bid Fails Before 1st Baby Formula MDL Trial

    An Illinois federal judge on Wednesday said Mead Johnson & Co. must face the first bellwether trial next week in multidistrict litigation over baby formula that allegedly was defective and harmed premature babies, rejecting the company's argument that the recent U.S. Supreme Court Monsanto decision blocks the plaintiff's claims.

  • August 06, 2026

    USPTO Leaders Reinstate Double Patenting Ax In Sanofi Case

    A panel including U.S. Patent and Trademark Office Director John Squires ruled Thursday that a Sanofi patent application must be rejected for double patenting, but questioned whether the rationale for the decision risks harming innovation and should be reconsidered by the Federal Circuit.

  • August 06, 2026

    Mark Zuckerberg's Foundation Can Arbitrate Gender Bias Suit

    A California federal judge on Thursday sent to arbitration claims that the foundation run by Meta CEO Mark Zuckerberg and his wife Priscilla Chan discriminated against women, saying the suit's sexual harassment claims weren't sufficiently severe or pervasive to invalidate the plaintiff's arbitration agreement.

  • August 06, 2026

    SEC Nets Win In Suit Over Ex-CEO's Alleged Revenue Scheme

    A Washington, D.C., federal judge on Thursday largely sided with the U.S. Securities and Exchange Commission in its civil enforcement case against the former CEO of RTI Surgical Holdings, finding he misled investors by failing to disclose that the surgical implant company regularly shipped orders early to artificially inflate its quarterly revenues.

  • August 06, 2026

    SpineFrontier CFO Sentenced To 4 Months In Kickback Case

    The former chief financial officer of spinal implant startup SpineFrontier was sentenced Thursday to four months in prison for his involvement in an alleged conspiracy to pay surgeons kickbacks disguised as consulting fees.

  • August 06, 2026

    GOP Sens. Vote To Hold Fauci In Contempt, AGs Open Probe

    A U.S. Senate committee voted along party lines Thursday to hold Dr. Anthony Fauci in contempt of Congress after he declined to answer questions about the government's handling of the pandemic, while the Florida, West Virginia and Louisiana attorneys general are investigating potential "self-dealing" by Fauci during the crisis.

  • August 06, 2026

    Judge Sets Feb. Trial In States' Generics Price-Fixing Suit

    A Connecticut federal judge has set a February trial date on claims from dozens of state attorneys general that generic-drug makers conspired to artificially inflate the prices of generic topical drugs.

  • August 06, 2026

    Goodwin, Covington Lead Braveheart Bio's $383M IPO

    Venture-backed biotechnology firm Braveheart Bio hit the public markets on Thursday after raising $383 million in its upsized initial public offering.

  • August 06, 2026

    Tarsus Bets Up To $800M On Alkeus In Retina Therapy Push

    Tarsus Pharmaceuticals Inc. said Thursday it has agreed to acquire privately held Alkeus Pharmaceuticals Inc. for up to approximately $800 million, expanding the Irvine, California-based eye care company's pipeline into retinal disease with an experimental treatment for Stargardt disease.

  • August 06, 2026

    Eli Lilly, Novo Nordisk Antitrust Suit Tossed By Texas Judge

    A Texas federal court has dismissed compounding pharmacy Strive Specialties Inc.'s antitrust lawsuit against Eli Lilly and Novo Nordisk, finding it failed to allege the companies blocked competition for GLP-1 medications.

  • August 06, 2026

    Judge OKs $35M Teva Deal In Delayed Generic Inhalers Suit

    A Massachusetts federal judge has approved an antitrust settlement that will see Teva Pharmaceuticals pay $35 million to resolve claims that it schemed to delay generic competition for its QVAR asthma inhalers.

  • August 06, 2026

    2025 Patent Litigation: A Year In Review

    The number of patent infringement lawsuits soared in 2025 as patent owners saw their fortunes change at the Patent Trial and Appeal Board, where petitioners filed significantly fewer America Invents Act challenges. Meanwhile, most patent infringement suits were brought in the Eastern District of Texas, which had considerably more filings than the Western District.

Expert Analysis

  • Court's HRSA Policy Reversal Leaves 340B Rules Murky

    Author Photo

    A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

  • USPTO's AI Search Pilot May Reshape Patent Filing Strategy

    Author Photo

    The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.

  • Peptide Policy Is Shifting Toward Sanctioned Compounding

    Author Photo

    The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.

  • Keys To Building Defensible Psychedelic Therapy Programs

    Author Photo

    Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.

  • Opinion

    State Bars Need To Get Specific About AI Confidentiality

    Author Photo

    Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.